ArticleTuberculosis (Edinburgh, Scotland)2012
High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv.
Article in Tuberculosis (Edinburgh, Scotland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 96 citations in OpenAlex.
- Development of machine learning models to identify potentially active compounds against tuberculosis.Scientific reports · 2025Article
- A high-throughput response to the SARS-CoV-2 pandemic.SLAS discovery : advancing life sciences R & D · 2024Article
- Identification and structure-activity relationships for a series of N, N-disubstituted 2-aminobenzothiazoles as potent inhibitors of S. aureus.Bioorganic & medicinal chemistry letters · 2023Article
- Identification of 2-Amino Benzothiazoles with Bactericidal Activity against Mycobacterium tuberculosis.Microbiology spectrum · 2023Article
- Human Kinase IGF1R/IR Inhibitor Linsitinib Controls the In Vitro and Intracellular Growth ofACS infectious diseases · 2022Article
- Machine Learning Models forMolecular pharmaceutics · 2022Article
- Drug Discovery forInternational journal of molecular sciences · 2021Review
- Evaluation of small molecule kinase inhibitors as novel antimicrobial and antibiofilm agents.Chemical biology & drug design · 2021Review
- Inhibitors of pantothenate synthetase ofRSC advances · 2020Review
- Molecule Property Analyses of Active Compounds forJournal of medicinal chemistry · 2020Review
- Identification of Anti-tuberculosis Compounds From Aurone Analogs.Frontiers in microbiology · 2020Article
- Article
- Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery.Molecular pharmaceutics · 2018Article
- Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance.The Journal of membrane biology · 2018Article
- A genome-wide structure-based survey of nucleotide binding proteins in M. tuberculosis.Scientific reports · 2017Article
- Identification of the anti-mycobacterial functional properties of piperidinol derivatives.British journal of pharmacology · 2017Article
- Learning from the past for TB drug discovery in the future.Drug discovery today · 2017Review
- Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).Drug discovery today · 2017Review
- Non-classical transpeptidases yield insight into new antibacterials.Nature chemical biology · 2017Article
- Machine Learning Model Analysis and Data Visualization with Small Molecules Tested in a Mouse Model of Mycobacterium tuberculosis Infection (2014-2015).Journal of chemical information and modeling · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Kinase targets are being pursued in a variety of diseases beyond cancer, including immune and metabolic as well as viral, parasitic, fungal and bacterial. In particular, there is a relatively recent interest in kinase and ATP-binding targets in Mycobacterium tuberculosis in order to identify inhibitors and potential drugs for essential proteins that are not targeted by current drug regimens. Herein, we report the high throughput screening results for a targeted library of approximately 26,000 compounds that was designed based on current kinase inhibitor scaffolds and known kinase binding sites. The phenotypic data presented herein may form the basis for selecting scaffolds/compounds for further enzymatic screens against specific kinase or other ATP-binding targets in Mycobacterium tuberculosis based on the apparent activity against the whole bacteria in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.